Tag:
anthrax
Latest Headlines
Latest Headlines
U.S. considers anthrax vaccine trials--for kids
The U.S. government for years has prepared for the threat of bioterrorism with a $1.1 billion stockpile of anthrax vaccine, which has been thoroughly tested with adults. Now the question is how to
Emergent BioSolutions gets gov't order for BioThrax
Emergent BioSolutions could earn up to $1.25 billion over the next 5 years for providing 44.8 million doses of its BioThrax anthrax vaccine to the U.S. government. The developer revealed in May the
BARDA continues support of pre- and post-exposure Anthrax vax
Intramuscular injection of an anthrax prophylactic has sustained the attention of the U.S. Biomedical Advanced Research & Development Authority (BARDA) to the tune of $68 million. New
U.S. increases Emergent BioSolutions' anthrax vax contract
Emergent BioSolutions is adding another 3.42 million doses to its 14.5 million-dose BioThrax contract with the U.S. government. The contract extension is worth an approximate $101 million; the
Combo anthrax/smallpox vax beats anthrax vax alone
Researchers have found that combination vaccines that protect against multiple maladies work better than vaccines for individual infections, including anthrax vaccines stockpiled by the U.S.
U.S. gets bioterror vax, funds capacity boost
The U.S. government continues to exercise its vaccine muscle. It has received a shipment of a smallpox vaccine for the national stockpile at the same time it is funding process development to
Elusys wins $143M contract for new anthrax treatment
The Department of Health and Human Services has awarded Elusys Therapeutics a contract worth up to $143 million for the development of a new anthrax therapy dubbed Anthim. The contract, which could
Dairy bacteria offers new vehicle for vaccine
An experimental oral vaccine has demonstrated that it may be able to protect people from an anthrax attack. This experimental vaccine is loaded onto bacteria found in dairy products to escape the
Emergent inks $29.7M anthrax vax contract
Emergent BioSolutions has inked a three-year, $29.7 million deal with Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases
Ivins' anthrax attack linked to vaccine criticism?
Federal officials believe that Senator Tom Daschle's objections to the anthrax vaccine being given to soldiers may have been a prime reason why he was targeted in the 2001 anthrax attacks. Daschle
